Peter Fedichev

Fedichev has a clear and repeated public vision around materially extending human lifespan by treating aging as an underlying biological/physical process rather than only managing age-related disease. The evidence includes a direct mission statement, multiple mechanistic claims about resilience, entropic damage, biological age, and lifespan limits, plus translational paths through biomarkers, therapeutic targets, and lifespan-extending compounds. The score is not higher because the evidence provided is mostly summarized or company/theory-aligned rather than showing a highly detailed public roadmap with milestones, timelines, or broad field-defining influence.

Primary citation metrics show substantial scientific influence, with h-index 38, 5,533 total citations, and multiple papers above 150 citations. However, the most-cited work is largely in physics/atomic gases rather than longevity, so the aging-specific impact is meaningful but not clearly field-defining.

Capital deployment is applicable because Fedichev is described as CEO/co-founder of Gero, a longevity-focused biotech company, which is some evidence of institution-building directed at aging. However, the provided evidence contains no disclosed personal investments, donations, fund allocations, or amounts, and the founder/mission claims are largely self-published or only weakly sourced for this dimension.

Fedichev shows a coherent and plausibly contrarian strategic thesis: applying physics-informed AI and large-scale longitudinal health data to aging as a systems/resilience problem rather than only a disease-by-disease or hallmarks framework. Founding Gero is a clear deployment vehicle, and the strategy has signs of field-shaping ambition through gerophysics framing, pharma collaborations, and claims of large-scale data infrastructure. However, the evidence is mostly self-published, lacks timing for the original bet, and provides limited independent proof that his choices were early, counterfactually important, or opened paths others were not seeing.

Field creation applies because Fedichev is described as founding/co-founding Gero, a longevity-focused biotech company using AI, human data, and physics-based models. However, the evidence for founding and broader field-building impact is mostly dossier/structured evidence with limited independent corroboration of the specific organizational achievement or its field-level effects, so the independence gate caps the score well below high.

Peter Fedichev shows some public conviction through strong, arguably controversial scientific claims about aging: framing COVID-19 as a disease of aging, asserting an intrinsic human lifespan limit tied to resilience loss, and publicly committing his founder identity to significantly extending lifespan. However, the evidence does not show major personal downside, sustained criticism, large relative financial risk, or concrete self-experimentation. This supports a modest bravery/conviction score rather than a high one.

Multiplier effect applies, but the evidence shows only moderate leverage: Fedichev founded Gero and appears to have built a collaborative scientific/company platform around physics-informed aging research. Bibliometrics and multi-author publications support some legitimacy and collaborator attraction, but there is little concrete evidence here of attracting major capital, policy attention, founders, broad public legitimacy, or follow-on projects beyond Gero. Independence-gate support for a higher score is limited.